For investors looking for chances in the stock market, the ideas of value investing give a reliable method. This approach, created by Benjamin Graham and widely followed by Warren Buffett, means finding companies selling for less than their true worth. The aim is to locate good businesses the market has incorrectly priced for now, giving an investor a "margin of safety." A useful method to use this thinking is by searching for stocks that show good basic condition and earnings but are valued in a way that seems separate from their real strength. This method helps remove "value traps," companies that are inexpensive for a cause, and centers on those that are possibly priced too low.
One company that recently appeared through a "Decent Value" search method is EXELIXIS INC (NASDAQ:EXEL), a biopharmaceutical company focused on cancer. The search aims to find stocks with a high valuation score, meaning they are inexpensive compared to their field and own basics, while still holding acceptable scores in earnings, financial condition, and expansion. This mix is key for value investors; a low price is only a chance if the company is fundamentally good and able to produce future gains.
Valuation Measures: An Interesting Starting Place
The heart of any value investment case is a good valuation, and Exelixis is notable here. Based on ChartMill's basic review, the company gets a good Valuation Score of 8 out of 10. This number comes from several measures that indicate the stock is priced cautiously.
- Price-to-Earnings (P/E) Ratio: At 15.14, the P/E ratio for Exelixis is much lower than the field average of 42.81. The company is valued lower than almost 95% of similar companies in the biotechnology field. It also sells at a lower price than the wider S&P 500 index, which has an average P/E of 24.75.
- Forward P/E Ratio: The view stays interesting looking forward. With a forward P/E of 13.37, Exelixis is less expensive than more than 96% of its field and the S&P 500's forward average of 22.10.
- Other Measures: The value argument is also backed by other important numbers. The company's Enterprise Value to EBITDA and Price to Free Cash Flow ratios are also in good areas, placed better than about 96% and 97% of field rivals, in order.
For a value investor, these numbers imply the market might be using a large price reduction to Exelixis, possibly missing its operational positives. This reduction gives the basic "margin of safety" that is central to the value investing idea.
Financial Condition: A Very Strong Base
An inexpensive stock is a dangerous choice if the company's financial position is poor. Value investing needs a base of financial soundness to make sure the business can handle bad times and keep working. Exelixis does very well here, having a very good Health Score of 9 out of 10.
The company's financial soundness is shown by several important points:
- No Debt: Exelixis has no debt, putting its Debt/Equity and Debt/Free Cash Flow ratios with the best in its field. This removes interest cost risk and gives great financial room to act.
- Strong Solvency: An Altman-Z score of 11.82 shows almost no short-term chance of failure and does better than 84% of field peers.
- Good Liquidity: With a Current Ratio of 3.56 and a Quick Ratio of 3.50, the company has more than enough liquid assets to meet its near-term needs.
This perfect financial position means Exelixis is not a company in trouble. Its low valuation is not because of financial danger, which fits exactly with the value investor's hunt for misjudged quality instead of failing businesses.
Earnings Ability: High-Grade Profit Strength
Earnings ability is the motor that pushes true value. A company must not only be sound but also skilled at turning sales into profit. Exelixis shows very good earnings ability, getting a high score of 9 in this area.
The company's skill to make returns is strong across several checks:
- Very Good Margins: Exelixis keeps a Gross Margin of 96.39%, an Operating Margin of 38.48%, and a Profit Margin of 33.73%. Each of these numbers is in the top 5% of its competitive biotechnology field.
- Effective Capital Use: The company's Return on Invested Capital (ROIC) of 29.21% is very good, doing better than 99% of peers. Importantly, this ROIC is much higher than its cost of capital, proving the company is making real shareholder value with each dollar used.
- Steady Cash Production: Exelixis has reported positive cash flow from operations for the last five straight years, showing the lasting nature of its profits.
For the value investor, this level of earnings ability supports the business model. It shows that the company's profits are of high grade and that it has competitive strengths, often called an economic moat, which are needed for long-term value building.
Expansion: A Steady Path
While pure value stocks sometimes miss expansion, the best choice mixes value with a sensible expansion path to help drive a new price assessment. Exelixis gets a Growth Score of 6, showing acceptable, though not fast, expansion possibilities.
The expansion picture is a blend of strong past results and slower future guesses:
- Past Expansion: The company has a very good recent history, with Earnings Per Share (EPS) growing almost 50% over the past year and at an average yearly rate of more than 51% in recent years. Sales have also grown at a good average of 18.63%.
- Future Guesses: Analyst estimates point to a slowing, with EPS expected to grow about 10% yearly and sales around 6%. While this shows a slowdown, it still points to an expanding, not reducing, company.
This expansion part is important because it deals with a key danger in value investing: no growth. Exelixis is not a no-expansion company selling at a big discount; it is a profitable, sound firm with a positive expansion view that is selling at a discount. This mix can be especially strong if the market starts to see the separation.
Conclusion: A Possibility for the Value Investor's List
Exelixis shows an interesting example for the ideas of value investing. The stock seems priced low based on normal profit measures when looked at next to both its field and the wider market. More importantly, this low price is joined with a very strong financial position, very good earnings ability, and a past of strong expansion. This mix of features, low price, sound condition, and high earnings, is exactly what searches like the "Decent Value" filter are made to find. It suggests the market might be pricing too low a high-grade business.
Certainly, investing in biotechnology has built-in dangers linked to clinical tests, rivalry, and patent ends. The seen slowing in expected expansion is a factor that needs close watch. However, for investors using a value-based method, EXELIXIS INC represents a stock where the basic numbers tell a story of strength that the present stock price may not completely show.
Interested in locating more stocks that match this description? You can use the "Decent Value" search yourself to see other possible chances by clicking here.
Disclaimer: This article is for information only and does not make financial advice, a suggestion to buy or sell any security, or a support of any investment plan. Investors should do their own study and talk with a qualified financial advisor before making any investment choices.